Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Gene expression company invests in biomarker discovery platforms

Share this on social media:

Genedata has announced a collaboration with TcLand Expression, a company in the field of gene expression biomarkers for autoimmune disorders and transplantation. As part of the collaboration, the Genedata Phylosopher and Expressionist biomarker discovery platforms will be integrated into TcLand Expression's computational infrastructure.

TcLand Expression is pioneering work in the field of personalised medicine for transplantation and autoimmune diseases. The company is developing gene expression signatures in collaboration with health care professionals and patients worldwide. The Genedata Expressionist and Phylosopher platforms will serve as a scalable core infrastructure supporting interdisciplinary biomarker identification, validation and mode-of-action studies. The platform will enable TcLand Expression's researchers to take a cross-technology approach by using automated workflows and integrated analysis tools to streamline the research workflow, from experimental design through to final results.

'Genedata’s biomarker platform complements perfectly our existing clinical and sample management systems,' commented Alessandra Cervino DPhil, VP Biostatistics and Bioinformatics at TcLand Expression. 'Genedata's integrated solution combines the flexibility needed in our R&D processes with the automation, traceability and 21 CFR part 11 compliance needed in our clinical studies.'